

Curriculum vitae for Elisabetta Renzoni

Elisabetta Renzoni was trained in Respiratory Medicine at the University of Siena, Italy. In 1999, she was awarded a European Respiratory Society research fellowship to work at the Royal Brompton ILD Unit. In 2006, she was appointed Consultant Physician at the Royal Brompton Hospital, and Honorary Senior Lecturer, Imperial College. In 2008, she was awarded with a PhD from Imperial College London.

Dr Renzoni is an ILD specialist and her clinical interests include connective tissue disease-associated lung involvement, idiopathic interstitial pneumonias, sarcoidosis, hypersensitivity pneumonitis and pulmonary vasculitis. Her research interests include translation and clinical research in pulmonary fibrosis. Dr Renzoni has led a multi-center randomized controlled clinical trial in collaboration with Aintree University and North Bristol ILD service, to study the effects of supplemental oxygen on quality of life in fibrotic lung diseases (NCT02286063), which has now been completed. She also leads a prospective study (NCT02136394) on the role of gastro-oesophageal reflux in pulmonary fibrosis in scleroderma, funded by the Scleroderma & Raynaud's UK. Dr Renzoni is a coinvestigator on a project aiming to develop an integrated staging system based on clinical and biomolecular markers for systemic sclerosis-associated lung disease (Arthritis and Research UK research).

Dr Renzoni regularly acts as an expert reviewer for research grant proposals and for respiratory/rheumatology journals, and is frequently invited to speak/chair scientific sessions at national and international meetings. She is a Fellow of the Higher Education Academy. She is an Associate Editor for *Respirology*. She is currently chair of the European Respiratory Society CTD-ILD group.

Publications

- 1) Stock CJW, Renzoni EA. Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. *Eur J Hum Genet*. 2018 Feb 23. doi: 10.1038/s41431-018-0104-8. [Epub ahead of print] PubMed PMID:29476163.
- 2) Piper AJ, Wort SJ, Renzoni EA, Kouranos V. Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep. *Respirology*. 2018 Apr;23(4):421-433. doi: 10.1111/resp.13273. Epub 2018 Feb 22. Review. PubMed PMID: 29471594.
- 3) Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU. Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. *EBioMedicine*. 2018 Feb;28:303-310.
- 4) Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU. Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. *Respirology*. 2018 Jan 12. doi: 10.1111/resp.13250. [Epub ahead of print] PubMed PMID: 29327393.
- 5) Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU. Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. *Respirology*. 2017 Dec 13. doi: 10.1111/resp.13231. [Epub ahead of print] PubMed PMID: 29237236.
- 6) Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassel D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis

from the multicentre PROFILE cohort study. *Lancet Respir Med.* 2017 Dec;5(12):946-955.

7) van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, Wapenaar M, Cottin V, Wijsenbeek MS. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. *Eur Respir J.* 2017 Oct 19;50(4).

8) Khroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, Maher TM, Devaraj A, Rice A, Renzoni EA, Nicholson AG. Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival. *Am J Surg Pathol.* 2017 Dec;41(12):1683-1689.

9) Bonifazi M, Gasparini S, Alfieri V, Renzoni EA. Pulmonary Sarcoidosis. *Semin Respir Crit Care Med.* 2017 Aug;38(4):437-449. doi: 10.1055/s-0037-1603766. Epub 2017 Jul 27. PubMed PMID: 28750459.

10) Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. *Eur Respir J.* 2017 Jul 5;50(1).

11) Saunders P, Tshipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. *Trials.* 2017 Jun 15;18(1):275.

12) Kouranos V, Jacob J, Nicholson A, Renzoni E. Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management. *J Clin Med.* 2017 Jun 15;6(6).

13) Ahmed Abdi B, Lopez H, Karrar S, Renzoni E, Wells A, Tam A, Etomi O, Hsuan JJ, Martin GR, Shiwen X, Denton CP, Abraham D, Stratton R. Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration. *Sci Rep.* 2017 Jun 1;7(1):2628.

14) Visca D, Tshipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA. Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. *Trials.* 2017 Apr 28;18(1):201.

15) Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU. Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. *Arthritis Rheumatol.* 2017 Apr 20.

16) Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. *Respiration.* 2017;93(6):415-423.

17) Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egnor W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. *J Allergy Clin Immunol Pract.* 2017 Mar 25. pii:S2213-2198(17)30035-1.

18) Bonifazi M, Montero MA, Renzoni EA. Idiopathic Pleuroparenchymal Fibroelastosis. *Curr Pulmonol Rep.* 2017;6(1):9-15.

19) Canu S, Alfieri V, Renzoni E. Patient-reported outcome measures in idiopathic pulmonary fibrosis: Where do we stand? *Respirology.* 2017 May;22(4):628-629.

20) Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, Blanchard A, Edwards LM, Stock C, Daccord C, Renzoni EA, Wells AU, Moffatt MF, Cookson WOC, Maher TM. Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2017 Jun 15;195(12):1640-1650.

21) Ward K, Spurr L, Goldman NR, Margaritopoulos GA, Kokosi M, Renzoni E, Chua F, Maher TM, Ward S, Wells AU. Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. *Respir Med.* 2016 Nov;120:131-133.

22) Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgässler KU, Herth FJ, Costabel U. Anti-acid treatment in patients with IPF: interpret results from post-hoc,

subgroup, and exploratory analyses with great caution - Authors' reply. *Lancet Respir Med*. 2016 Sep;4(9):e48.

23) van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS. Cough in idiopathic pulmonary fibrosis. *Eur Respir Rev*. 2016 Sep;25(141):278-86.

24) Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM. Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2016 Apr 18. [Epub ahead of print] PubMed PMID: 27089018.

25) Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. *Lancet Respir Med*. 2016 Mar 31.

26) Conti C, Montero-Fernandez A, Borg E, Osadolor T, Viola P, De Lauretis A, Stock CJ, Bonifazi M, Bonini M, Caramori G, Lindahl G, Blasi FB, Nicholson AG, Wells AU, Sestini P, Renzoni E. Mucins MUC5B and MUC5AC in Distal Airways and Honeycomb Spaces: Comparison among Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia, Fibrotic Nonspecific Interstitial Pneumonitis, and Control Lungs. *Am J Respir Crit Care Med*. 2016 Feb 15;193(4):462-4.

27) Evans IC, Barnes JL, Garner IM, Pearce DR, Maher TM, Shiwen X, Renzoni EA, Wells AU, Denton CP, Laurent GJ, Abraham DJ, McAnulty RJ. Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis. *Clin Sci (Lond)*. 2016 Apr 1;130(8):575-86.

28) Garner J, George PM, Renzoni E. Cough in interstitial lung disease. *Pulm Pharmacol Ther*. 2015 Dec;35:122-8.

29) Schiza S, Mermigkis C, Margaritopoulos GA, Daniil Z, Harari S, Poletti V, Renzoni EA, Torre O, Visca D, Bouloukaki I, Sourvinos G, Antoniou KM. Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night. *Eur Respir Rev*. 2015 Jun;24(136):327-39.

30) Patel AS, Siegert RJ, Bajwah S, Brignall K, Gosker HR, Moxham J, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. *J Clin Epidemiol*. 2015 Sep;68(9):1019-27.

31) Staitieh BS, Renzoni EA, Veeraraghavan S. Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. *Ann Med*. 2015 Mar;47(2):100-5. doi: 10.3109/07853890.2014.991751. Epub 2015 Jan 22. Review. PubMed PMID: 25613169; PubMed Central PMCID: PMC4638420.

32) Bonifazi M, Bravi F, Gasparini S, La Vecchia C, Gabrielli A, Wells AU, Renzoni EA. Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies. *Chest*. 2015 Mar 1;147(3):778-91.

33) Staitieh BS, Renzoni EA, Veeraraghavan S. Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. *Ann Med*. 2015 Jan 22:1-6.

34) Renzoni E, Srihari V, Sestini P. Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings. *F1000Prime Rep*. 2014 Aug 1;6:69. doi:10.12703/P6-69.

35) Keir GJ, Walsh SL, Gatzoulis MA, Marino PS, Dimopoulos K, Alonso R, Raposeiras-Roubin S, Renzoni EA, Maher TM, Wells AU, Wort SJ. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. *Sarcoidosis Vasc Diffuse Lung Dis*. 2014 Jul 8;31(2):82-90.

36) Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, Foley C, Yanez-Lopez M, Babalis D, Marino P, Maher TM, Renzoni EA, Spencer L, Elliot CA, Birring SS, O'Reilly K, Gatzoulis MA, Wells AU, Wort SJ; for the BPHIT Study Group. Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. *Am J Respir Crit Care Med*. 2014 Jul 15;190(2):208-217.

37) De Lauretis A, Renzoni EA. Molecular Biomarkers in Interstitial Lung Diseases. *Mol Diagn Ther*. 2014 Jun 17.

38) Walsh SL, Wells AU, Sverzellati N, Keir GJ, Calandriello L, Antoniou KM, Copley SJ, Devaraj A, Maher TM, Renzoni E, Nicholson AG, Hansell DM. An integrated clinoradiological staging system for pulmonary sarcoidosis: a case-cohort study. *Lancet Respir Med*. 2014 Feb;2(2):123-30.

39) Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in

the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol.* 2014 Apr;41(4):792-8.

40) Keir G, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA. Rituximab in severe, treatment-refractory interstitial lung disease. *Respirology* 2014 Apr;19(3):353-9.

41) Keir GJ, Garfield B, Hansell DM, Loebinger MR, Wilson R, Renzoni EA, Wells AU, Maher TM. Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. *Thorax.* 2013 Sep 12.

42) Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, Bou-Gharios G, Nicholson AG, Denton CP, Grutters JC, Maher TM, Wells AU, Abraham DJ, Renzoni EA. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. *Respir Res.* 2013 Aug 2;14:80. doi: 10.1186/1465-9921-14-80.

43) Stock C, Sato H, Fonseca C, Lindahl GE, Molyneaux PH, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA. The Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. *Thorax.* 2013 May;68(5):436-41.

44) De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NSL, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA. Serum interleukin6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. *J Rheumatol.* 2013 Apr;40(4):435-46.

45) Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. *Thorax.* 2013 Mar 20. doi: 10.1136/thoraxjnl-2013-203265.

46) Corte TJ, Wort SJ, Talbot S, Macdonald PM, Hansel DM, Polkey M, Renzoni E, Maher TM, Nicholson AG, Wells AU. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. *Sarcoidosis Vasc Diffuse Lung Dis.* 2012 Mar;29(1):41-50.

47) Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. *Thorax.* 2013 Jan;68(1):57-65.

48) Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax.* 2012 Nov;67(11):938-40.

49) Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. *Int J Rheumatol.* 2012;2012:121439. doi: 10.1155/2012/121439. Epub 2012 Sep 3.

45) Elia D, Kelly JL, Martolini D, Renzoni EA, Boutou AK, Chetta A, Polkey MI, Hopkinson NS. Respiratory muscle fatigue following exercise in patients with interstitial lung disease. *Respiration.* 2013;85(3):220-7.

51) Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. *Thorax.* 2012 Sep;67(9):804-10.

52) Lota HK, Dusmet M, Steele K, Wells AU, Nicholson AG, Hansell DM, Renzoni EA. A rapidly growing lung mass with air crescent formation. *Thorax.* 2013 Apr;68(4):394-5.

53) Reddy TL, Tominaga M, Hansell DM, von der Thusen J, Rassl D, Parfrey H, Guy S, Twentyman O, Rice A, Maher TM, Renzoni EA, Wells AU, Nicholson AG. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. *Eur Respir J.* 2012 Aug;40(2):377-85.

54) Sozio F, Rossi A, Weber E, Abraham DJ, Nicholson AG, Wells AU, Renzoni EA, Sestini P. Morphometric analysis of intralobular, interlobular and pleural lymphatics in normal human lung. *J Anat.* 2012 Apr;220(4):396-404.

55) Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. *Eur Respir J.* 2012 Sep;40(3):641-8.

- 56) Corte TJ, Wort SJ, MacDonald PS, Edey A, Hansell DM, Renzoni E, Maher TM, Nicholson AG, Bandula S, Bresser P, Wells AU. Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. *Respirology*. 2012 May;17(4):674-80.
- 57) Rowan C, Hansell DM, Renzoni E, Maher TM, Wells AU, Polkey MI, Rehal PK, Ibrahim WH, Kwong GN, Colby TV, Pistolesi M, Bigazzi F, Comin CE, Nicholson AG. Diffuse cystic lung disease of unexplained cause with coexistent small airway disease: a possible causal relationship? *Am J Surg Pathol*. 2012 Feb;36(2):228-34.
- 58) Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, Wells AU, Renzoni EA. Ambulatory oxygen in interstitial lung disease. *Eur Respir J*. 2011 Oct;38(4):987-90.
- 59) Corte TJ, Copley SJ, Desai SR, Zappala CJ, Hansell DM, Nicholson AG, Colby TV, Renzoni E, Maher TM, Wells AU. Significance of connective tissue disease features in idiopathic interstitial pneumonia. *Eur Respir J*. 2012 Mar;39(3):661-8.
- 60) de Lauretis A, Veeraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? *Chron Respir Dis*. 2011;8(1):53-82
- 61) Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2011 Jan;44(1):1-10.
- 62) Verma H, Nicholson AG, Kerr KM, Dempsey OJ, Gibbs AR, Campbell I, Black F, Rassl D, Rice AJ, Renzoni EA, Wells AU, Hansell DM. Alveolar proteinosis with hypersensitivity pneumonitis: a new clinical phenotype. *Respirology*. 2010 Nov;15(8):1197-202.
- 63) Corte TJ, Ellis R, Renzoni EA, Hansell DM, Nicholson AG, du Bois RM, Wells AU. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. *Sarcoidosis Vasc Diffuse Lung Dis*. 2009 Jul;26(2):132-8.
- 64) Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2011 Jan;44(1):1-10.
- 65) Asher MI, Stewart AW, Mallol J, Montefort S, Lai CK, Ait-Khaled N, Odhiambo J; ISAAC Phase One Study Group. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. *Respir Res*. 2010 Jan 21;11:8.
- 66) Rossi A, Sozio F, Sestini P, Renzoni EA, Khan K, Denton CP, Abraham DJ, Weber E. Lymphatic and blood vessels in scleroderma skin, a morphometric analysis. *Hum Pathol*. 2010 Mar;41(3):366-74.
- 67) Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. *Eur Respir J*. 2010 Apr;35(4):830-6.
- 68) Renzoni EA. Interstitial lung disease in systemic sclerosis. *Monaldi Arch Chest Dis*. 2007 Dec;67(4):217-28.
- 69) Ricci A, Graziano P, Bronzetti E, Saltini C, Sciacchitano S, Cherubini E, Renzoni E, Du Bois RM, Grutters JC, Mariotta S. Increased pulmonary neurotrophin protein expression in idiopathic interstitial pneumonias. *Sarcoidosis Vasc Diffuse Lung Dis*. 2007 Mar;24(1):13-23. PubMed PMID: 18069415.
- 70) Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. *Arthritis Rheum*. 2007 Dec;56(12):4189-94.
- 71) Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ. A polymorphism in the CTGF promoter region associated with systemic sclerosis. *N Engl J Med*. 2007 Sep 20;357(12):1210-20.
- 72) Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. *Matrix Biol*. 2007 Oct;26(8):625-32.
- 73) Spagnolo P, Sato H, Grutters JC, Renzoni EA, Marshall SE, Ruven HJ, Wells AU, Tzouveleakis A, van Moersel CH, van den Bosch JM, du Bois RM, Welsh KI. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. *Tissue Antigens*. 2007 Sep;70(3):219-27.

- 74) Fonseca C, Renzoni E, Sestini P, Pantelidis P, Lagan A, Bunn C, McHugh N, Welsh KI, Du Bois RM, Denton CP, Black C, Abraham D. Endothelin axis polymorphisms in patients with scleroderma. *Arthritis Rheum.* 2006 Sep;54(9):3034-42.
- 75) Abdallah AM, Renzoni EA, Anevclavis S, Lagan AL, Munkonge FM, Fonseca C, Black CM, Briggs D, Wells AU, Marshall SE, McHugh N, du Bois RM, Welsh KI. A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis. *Int J Immunogenet.* 2006 Jun;33(3):155-61.
- 76) Menon RP, Menon MR, Shi-Wen X, Renzoni E, Bou-Gharios G, Black CM, Abraham DJ. Hammerhead ribozyme-mediated silencing of the mutant fibrillin-1 of tight skin mouse: insight into the functional role of mutant fibrillin-1. *Exp Cell Res.* 2006 May 15;312(9):1463-74.
- 77: Shi-wen X, Stanton LA, Kennedy L, Pala D, Chen Y, Howat SL, Renzoni EA, Carter DE, Bou-Gharios G, Stratton RJ, Pearson JD, Beier F, Lyons KM, Black CM, Abraham DJ, Leask A. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. *J Biol Chem.* 2006 Apr21;281(16):10715-26.
- 78: Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. *Am J Pathol.* 2005 Dec;167(6):1699-711.
- 79: Spagnolo P, Renzoni EA, Wells AU, Copley SJ, Desai SR, Sato H, Grutters JC, Abdallah A, Taegtmeyer A, du Bois RM, Welsh KI. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. *Am J Respir Crit Care Med.* 2005 Sep 15;172(6):721-8. Epub 2005 Jun 23. PubMed PMID: 15976369.
- 80: Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, Lazaridis K, Edwards DR, Leask A, Eastwood M, Leoni P, Renzoni EA, Bou Gharios G, Abraham DJ, Black CM. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II Transforming growth factor- β receptor (T β RII Δ k). *J Biol Chem.* 2005 Apr 22;280(16):16053-65.
- 81: Renzoni EA, Abraham DJ, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, Wells AU, Veeraraghavan S, Nicholson AG, Denton CP, Leask A, Pearson JD, Black CM, Welsh KI, du Bois RM. Gene expression profiling reveals novel TGF β targets in adult lung fibroblasts. *Respir Res.* 2004 Nov 30;5:24.
- 82: Lagan AL, Pantelidis P, Renzoni EA, Fonseca C, Beirne P, Taegtmeyer AB, Denton CP, Black CM, Wells AU, du Bois RM, Welsh KI. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. *Rheumatology (Oxford).* 2005 Feb;44(2):197-201.
- 83: Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympany P, Thomas AQ, Roldan J, Scott TA, Blackwell TS, Phillips JA 3rd, Loyd JE, du Bois RM. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. *Thorax.* 2004 Nov;59(11):977-80.
- 84: Veeraraghavan S, Renzoni EA, Jeal H, Jones M, Hammer J, Wells AU, Black CM, Welsh KI, du Bois RM. Mapping of the immunodominant T cell epitopes of the protein topoisomerase I. *Ann Rheum Dis.* 2004 Aug;63(8):982-7.
- 85: Ujita M, Renzoni EA, Veeraraghavan S, Wells AU, Hansell DM. Organizing pneumonia: peribubular pattern at thin-section CT. *Radiology.* 2004 Sep;232(3):757-61.
- 86: Renzoni EA. Neovascularization in idiopathic pulmonary fibrosis: too much or too little? *Am J Respir Crit Care Med.* 2004 Jun 1;169(11):1179-80.
- 87: Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. *Mol Biol Cell.* 2004 Jun;15(6):2707-19.
- 88: Xu SW, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, Bou-Gharios G, Denton CP, du Bois RM, Black CM, Leask A, Abraham DJ. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. *J Biol Chem.* 2004 May 28;279(22):23098-103.

- 89: Sato H, Lagan AL, Alexopoulou C, Vassilakis DA, Ahmad T, Pantelidis P, Veeraraghavan S, Renzoni E, Denton C, Black C, Wells AU, du Bois RM, Welsh KI. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. *Arthritis Rheum.* 2004 Feb;50(2):558-64.
- 90: Veeraraghavan S, Latsi PI, Wells AU, Pantelidis P, Nicholson AG, Colby TV, Haslam PL, Renzoni EA, du Bois RM. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. *Eur Respir J.* 2003 Aug;22(2):239-44. PubMed PMID: 12952254.
- 91: Spagnolo P, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P, Abdallah A, Gramiccioni E, Ruven HJ, du Bois RM, Welsh KI. C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. *Am J Respir Crit Care Med.* 2003 Nov 15;168(10):1162-6.
- 92: Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2002;(4):CD001495. Review. PubMed PMID: 12519559.
- 93: Renzoni EA, Walsh DA, Salmon M, Wells AU, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, Black CM, Du Bois RM. Interstitial vascularity in fibrosing alveolitis. *Am J Respir Crit Care Med.* 2003 Feb 1;167(3):438-43.
- 94: Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable COPD. *Cochrane Database Syst Rev.* 2000;(3):CD001495. Review. Update in: *Cochrane Database Syst Rev.* 2002;(4):CD001495. PubMed PMID: 10908502.
- 95: Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, Welsh K, Bunn C, Knight C, Foley P, du Bois RM. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. *Arthritis Rheum.* 2000 Jul;43(7):1633-40.
- 96: Forastiere F, Pistelli R, Sestini P, Fortes C, Renzoni E, Rusconi F, Dell'Orco V, Ciccone G, Bisanti L. Consumption of fresh fruit rich in vitamin C and wheezing symptoms in children. SIDRIA Collaborative Group, Italy (Italian Studies on Respiratory Disorders in Children and the Environment). *Thorax.* 2000 Apr;55(4):283-8.
- 97: Rusconi F, Galassi C, Corbo GM, Forastiere F, Biggeri A, Ciccone G, Renzoni E. Risk factors for early, persistent, and late-onset wheezing in young children. SIDRIA Collaborative Group. *Am J Respir Crit Care Med.* 1999 Nov;160(5 Pt 1):1617-22.
- 98: Renzoni E, Forastiere F, Biggeri A, Viegi G, Bisanti L, Chellini E, Ciccone G, Corbo G, Galassi C, Rusconi F, Sestini P. Differences in parental- and self-report of asthma, rhinitis and eczema among Italian adolescents. SIDRIA collaborative group. *Studi Italiani sui Disordini Respiratori dell' Infanzia e l'Ambiente.* *Eur Respir J.* 1999 Sep;14(3):597-604.
- 99: Agabiti N, Mallone S, Forastiere F, Corbo GM, Ferro S, Renzoni E, Sestini P, Rusconi F, Ciccone G, Viegi G, Chellini E, Piffer S. The impact of parental smoking on asthma and wheezing. SIDRIA Collaborative Group. *Studi Italiani sui Disturbi Respiratori nell'Infanzia e l'Ambiente.* *Epidemiology.* 1999 Nov;10(6):692-8.
- 100: Ciccone G, Forastiere F, Agabiti N, Biggeri A, Bisanti L, Chellini E, Corbo G, Dell'Orco V, Dalmaso P, Volante TF, Galassi C, Piffer S, Renzoni E, Rusconi F, Sestini P, Viegi G. Road traffic and adverse respiratory effects in children. SIDRIA Collaborative Group. *Occup Environ Med.* 1998 Nov;55(11):771-8.
- 101: Renzoni E, Rottoli P, Coviello G, Perari MG, Galeazzi M, Vagliasindi M. Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease. *Clin Rheumatol.* 1997 Nov;16(6):570-7.
- 102: Renzoni E, Beltrami V, Sestini P, Pompella A, Menchetti G, Zappella M. Brief report: allergological evaluation of children with autism. *J Autism Dev Disord.* 1995 Jun;25(3):327-33. PubMed PMID: 7559298.
- 103: Sestini P, Renzoni E, Rossi M, Beltrami V, Vagliasindi M. Multimedia presentation of lung sounds as a learning aid for medical students. *Eur Respir J.* 1995 May;8(5):783-8. PubMed PMID: 7544742.